Navigation Links
Vaccine for brain tumors shows promising results

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain, known as glioma, has shown promising results in preliminary data from a clinical trial at UCSF Medical Center.

Findings from the first group of six patients in the study, being conducted at the UCSF Brain Tumor Research Center, showed that vitespen (trademarked as Oncophage), a vaccine made from the patient's own tumor, was associated with tumor-specific immune response in patients with recurrent, high-grade glioma.

Glioma is a type of primary tumor that arises from the glial cells, the connective tissue cells that surround and support nerve cells. The most common site of involvement of a glioma is the brain. Malignant glioma is currently a fatal disease.

The trial results are being presented at the Immunotherapy Task Force Meeting, sponsored by the Society of Neuro-Oncology and the Joint Section of Tumors, during the Society's 11th annual scientific meeting in Orlando, Fla., on November 16, 2006.

"This is the first documentation of a glioma-specific immune response after vaccination with vitespen," said Andrew T. Parsa, MD, PhD, assistant professor in the UCSF Department of Neurological Surgery and principal investigator of the trial.

"Based on preliminary observation of patients in the first cohort, the tumor-specific immune response evoked by vitespen vaccination may be associated with clinical benefit in these patients with recurrent glioma, including improved progression-free survival and overall survival compared with historical controls. Further studies are certainly warranted to definitively determine the benefit of vitespen in this patient population," he said.

Derived from each individual's tumor, vitespen contains the "fingerprint" of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. The vaccine is
'"/>

Source:University of California - San Francisco


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. EuroVacc 02 HIV Vaccine Trial Begins
9. Active Vaccine Prevents Mice From Developing Prion Disease
10. New Vaccine To Be Used For First Time In Polio Outbreak Response
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
(Date:7/23/2008)...lands published online in The FASEB Journal ( ht...an saliva that greatly speeds wound healing. This ...hronic wounds related to diabetes and other disord...ddition, because the compounds can be mass produce...antibiotic creams and rubbing alcohol. , "We hop...
(Date:7/23/2008)...rom the lower abdomen and inner thigh through lipo...m cells, with higher stem cell concentrations than...d study in August,s Plastic and Reconstructive Su...an Society of Plastic Surgeons (ASPS). This is the...ssues from different areas of the body vary in ste...
(Date:7/23/2008)... Dan Shain is redefining the term "summer action h...y Amazon planned, all in the name of scientific re...ociate professor of biology at RutgersCamden, trav...nges, and returns home with treasure. He,s mined ...ood in leech-infested tropical waters; and studied...
(Date:7/23/2008)...include confirmation that East Java,s "Lusi" mud v...he Banjar Panji-1 well; evidence of the oldest hum...Nile delta; analysis of Yellowstone,s hotspot; and...es occur in the Snake River Plain. GSA Today ,s s...am in Grand Canyon on sandbar ecosystems along the...
Breaking Biology News(10 mins):Licking your wounds: Scientists isolate compound in human saliva that speeds wound healing 2Want a reason to love your lower belly fat? It's rich in stem cells 2Rutgers biologist to study worms in Amazon, glaciers 2August 2008 Geology and GSA Today media highlights 2August 2008 Geology and GSA Today media highlights 3August 2008 Geology and GSA Today media highlights 4August 2008 Geology and GSA Today media highlights 5August 2008 Geology and GSA Today media highlights 6August 2008 Geology and GSA Today media highlights 7August 2008 Geology and GSA Today media highlights 8August 2008 Geology and GSA Today media highlights 9August 2008 Geology and GSA Today media highlights 10August 2008 Geology and GSA Today media highlights 11August 2008 Geology and GSA Today media highlights 12CASTLE Study Showed Similar Efficacy Between Once Daily REYATAZ 28R 29 28atazanavir sulfate 29 ritonavir and Twice Daily lopinavir ritonavir at 48 We 1334 1CASTLE Study Showed Similar Efficacy Between Once Daily REYATAZ 28R 29 28atazanavir sulfate 29 ritonavir and Twice Daily lopinavir ritonavir at 48 We 1334 2CASTLE Study Showed Similar Efficacy Between Once Daily REYATAZ 28R 29 28atazanavir sulfate 29 ritonavir and Twice Daily lopinavir ritonavir at 48 We 1334 3CASTLE Study Showed Similar Efficacy Between Once Daily REYATAZ 28R 29 28atazanavir sulfate 29 ritonavir and Twice Daily lopinavir ritonavir at 48 We 1334 4CASTLE Study Showed Similar Efficacy Between Once Daily REYATAZ 28R 29 28atazanavir sulfate 29 ritonavir and Twice Daily lopinavir ritonavir at 48 We 1334 5CASTLE Study Showed Similar Efficacy Between Once Daily REYATAZ 28R 29 28atazanavir sulfate 29 ritonavir and Twice Daily lopinavir ritonavir at 48 We 1334 6Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment Experienced HIV Infected Patients 11226 1Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment Experienced HIV Infected Patients 11226 2Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment Experienced HIV Infected Patients 11226 3Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment Experienced HIV Infected Patients 11226 4VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 3091 1VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 3091 2Gene plays Jekyll and Hyde in brain cancer 11223 1Gene plays Jekyll and Hyde in brain cancer 11223 2Gene plays Jekyll and Hyde in brain cancer 11223 3
...ck,s horticultural research arm Warwick HRI have c...t DNA that will provide a massive boost to the wor...libraries is the largest of its type in the world ...e. , The Warwick researchers have set up a new spi...ited" to develop this powerful new resource for pl...
...apy for breast cancer , A team from the Universit...t by using a cancer vaccine based on the bacterium...stablished breast tumors. Cancer vaccines, which a...by boosting an immune response against tumor-assoc..., led by Yvonne Paterson, PhD, Professor of Microb...
...y biologists at New York University,s Center for C...ith researchers at Harvard University, the Max Pla...ut a preliminary molecular diagram of the early st...ime a global look at how a single cell begins its ...are reported in the August 11 issue of the journal...
...increases blood pressure by activating tiny pores,... levels of sodium to be reabsorbed into the blood,...e found. The findings shed light on the underlying...help explain why patients with hypertension linked...ements in order to keep their high blood pressure ...
Other Biology News:New plant DNA libraries provides massive boost to world's plant researchers 2Breast tumors in mice eradicated using cancer vaccine 2Breast tumors in mice eradicated using cancer vaccine 3NYU biologists map out early stages of embryo formation 2Enzyme affects hypertension by controlling salt levels in body 2Enzyme affects hypertension by controlling salt levels in body 3
(Date:7/24/2008)...re/ -- The Global Probiotics Council,(GPC), a comm...ult Honsha,Co., Ltd., announced the two awardees w...rant for Probiotics Research (YIGPRO) today. The p...who will continue to contribute to,the advancement...United,States., Ajay S. Gulati, MD, an Assistant ...
(Date:7/24/2008)... Important Advance in Radiofrequency ...if., July 24 /- PEAK Surgical, Inc., ...tissue dissection system,based on a proprietary te...rug Administration has granted the company 510(k) ... use in general surgery. The PEAK Surgery System,c...
(Date:7/24/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched ceftazidime for injectio...m antibiotic. Sagent will offer ceftazidime in 1,a...ge vials. According to,IMS data, 2007 sales of inj...ximately $45.7 million., "Sagent is proud to be p...
(Date:7/24/2008)...swire-FirstCall/ -- United,Therapeutics Corporatio...lease its 2008 second quarter financial results be...., United Therapeutics will host a half-hour tele.... Eastern Time. The teleconference is accessible,b...rs dialing,1-706-679-8129. A rebroadcast of the te...
Breaking Biology Technology:Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research 2Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research 3Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research 4PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery 4Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
...segment of a national and international pipeline t...announcement that CellCura, Inc. , a Norwegian bi...e opening a location in Madison,s University Rese...any to start or locate in Wisconsin during the pas...nal search and will open in Madison with a small t...
...t two Google products do not infringe on patents...ted a motion to dismiss a lawsuit brought against ...udge John Shabaz has ruled that Google,s AdSense ...nts held by the Madison-based HyperPhrase Technolo...e patents, which pertain to a technology that crea...
...ppear to have too many worries right now. As the C...ies that dominates classified advertising, he lead...orldwide. And since the dismissal of a housing dis...icago, the organization could have one less contro...n much of the credit for designing the company,s m...
...n leaves behind an economic year in which some new...off, and the state,s tech economy positioned itsel...k, 2007 should be even better, but the investment ...ed to turn a cold shoulder to ideas that would hur...ketplace. What,s in store for the New Year? Severa...
Other Biology Technology:CellCura could start an invasion of stem cell firms 2CellCura could start an invasion of stem cell firms 3Wisconsin judge dismisses patent suit vs. Google 2Craigslist exec strives to keep the Internet neutral 2Craigslist exec strives to keep the Internet neutral 3Craigslist exec strives to keep the Internet neutral 4Wisconsin's high-growth economy: '07 predictions 2Wisconsin's high-growth economy: '07 predictions 3Wisconsin's high-growth economy: '07 predictions 4
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly.
The Model 111 mini IEF cell is an apparatus dedicated to general analytical isoelectric focusing (IEF) using polyacrylamide or agarose slab gels. The cell includes the electrophoresis chamber and lid
...k FXP is the latest entry in the Biomek line. With...ional accuracy and increased robustness, it can me... be configured with either one or two pipetting po...ets the standard for flexible laboratory solutions...
...rating a wide range of next-generation features in...standard for flexible laboratory solutions. It put...ting, dilution, dispensing, and integrations into...flexible as it is efficient and economical. The Bi...
Biology Products: